Secondary Logo

Share this article on:


Optometry and Vision Science: January 2001 - Volume 78 - Issue 1 - p 5
Back to Top | Article Outline

Carl Zeiss and Biometric Imaging Map Their Future

Zeiss Humphrey Systems and Zeiss Ophthalmic Instruments, divisions of Carl Zeiss, have announced a long-term agreement with Biometric Imaging, Inc. to cooperate in the development of a method for measuring metabolic activities in the human eye. The process, known as Metabolic Mapping, quantifies intra-cellular metabolism in living tissue, and translates measurements into digital images, comparing areas of normal function to areas of depressed function.

Ophthalmic Metabolic Mapping has the potential of enhancing early diagnosis and providing titration of therapeutics, taking diagnosis and treatment of ocular disease to a higher level. Anticipated applications include methods for diagnosing and managing such diseases as diabetic retinopathy, glaucoma, and other ophthalmic conditions.

Back to Top | Article Outline

BigShot Improves Computer Access

Ai Squared, the computer software development company, has created the BigShot Magnifier to give low vision patients better computer viewing capabilities. Normally sighted computer users who experience regular, screen-related eyestrain may also benefit from BigShot. The BigShot Magnifier operates like a virtual magnifying glass, as the software increases the sizes of all elements on a computer screen and provides 20 adjustable levels of enlargement from 105 to 200%. For more information, visit

Back to Top | Article Outline

Ciba Vision’s Visudyne Wins Popular Science Award

Visudyne therapy, used to treat patients with wet age-related macular degeneration and recently approved by the U.S. Food and Drug Administration (FDA), was selected by the editors of Popular Science as one of the 100 most remarkable new products, technological developments, and scientific achievements of the year. Visudyne therapy is a two-step procedure, where it is first injected intravenously into the patient’s arm and then activated by shining a non-thermal laser light into the patient’s eye.

The editors of Popular Science selected the 100 winners from thousands of products and developments in a total of 10 categories for the “Best of What’s New” Award in 2000 and these winners were featured in the cover story of the scientific consumer magazine’s December issue. Visudyne therapy was chosen to receive the award in the area of Medical Technology.

Back to Top | Article Outline

VPL and WHO form Strategic Alliance

Veterinary Products Laboratories (VPL) and Wound Healing of Oklahoma (WHO) have announced that they will work together to develop a novel, surgical implant for the treatment of glaucoma in animals. VPL will develop and market the implant to veterinary ophthalmologists both domestically and internationally. Dr. Craig Woods, DVM, MS, project leader and Director of Technical Affairs for VPL states, “The device will be used for treatment of glaucoma and potentially for prevention in high-risk, predisposed patients.” VPL has initiated trials and anticipates market introduction in 2001, after tailoring the device for veterinary patients and the manufacturing aspects have been established.

WHO will focus on providing proprietary, science-based solutions for human medicine through the discovery, development, and commercialization of novel polymer technologies. The company invented the investigational device for glaucoma and will assist VPL in the development of this program. For more information, visit or call (888) 241-9545.

© 2001 American Academy of Optometry